Vahanian & Associates Financial Planning Inc. Halozyme Therapeutics, Inc. Transaction History

Vahanian & Associates Financial Planning Inc.

$24.5 Million
Q4 2023

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 Apr 17, 2023	SELL	$32.86 - $55.7 $122,403 - $207,482	-3,725 Reduced 40.38%	5,500 $210,000
Q4 2022 Jan 31, 2023	BUY	$40.06 - $59.44 $369,553 - $548,334	9,225 New	9,225 $524,000

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$838 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$613 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$315 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$193 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$162 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vahanian & Associates Financial Planning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vahanian & Associates Financial Planning Inc. with notifications on news.

Account